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CD4 T cell-dependent antibody responses are essential for limiting Plasmodium parasite
replication and the severity of malaria; however, the factors that regulate humoral immunity
during highly inflammatory, Th1-biased systemic infections are poorly understood. Using
genetic and biochemical approaches, we show that Plasmodium infection-induced type I
interferons limit T follicular helper accumulation and constrain anti-malarial humoral immu-
nity. Mechanistically we show that CD4 T cell-intrinsic type I interferon signaling induces T-
bet and Blimp-1 expression, thereby promoting T regulatory 1 responses. We further show
that the secreted effector cytokines of T regulatory 1 cells, IL-10 and IFN-γ, collaborate to
restrict T follicular helper accumulation, limit parasite-specific antibody responses, and
diminish parasite control. This circuit of interferon-mediated Blimp-1 induction is also opera-
tional during chronic virus infection and can occur independently of IL-2 signaling. Thus,
type I interferon-mediated induction of Blimp-1 and subsequent expansion of T regulatory 1
cells represent generalizable features of systemic, inflammatory Th1-biased viral and para-
sitic infections that are associated with suppression of humoral immunity.
Author Summary
Humoral immunity is essential for host resistance to pathogens that trigger highly inflam-
matory immune responses, including Plasmodium parasites, the causative agents of
malaria. Long-lived, secreted antibody responses depend on a specialized subset of CD4 T
cells called T follicular helper (Tfh) cells. However, anti-Plasmodium humoral immunity
is often short-lived, non-sterilizing, and immunity rapidly wanes, leaving individuals sus-
ceptible to repeated bouts of malaria. Here we explored the relationship between inflam-
matory type I interferons, the regulation of pathogen-specificCD4 T cell responses, and
humoral immunity using models of experimentalmalaria and systemic virus infection.
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We identified that type I interferons promote the formation and accumulation of patho-
gen-specificCD4 T regulatory 1 cells that co-express interferon-gamma and interleukin-
10. Moreover, we show that the combined activity of interferon-gamma and interleukin-
10 limits the magnitude of infection-inducedTfh responses, the secretion of parasite-spe-
cific secreted antibody, and parasite control. Our study provides new insight into the regu-
lation of T regulatory 1 responses and humoral immunity during inflammatory immune
reactions against systemic infections.
Introduction
Malaria, caused by mosquito-borne Plasmodium parasites, remains a significant burden on
public health that is responsible for over 400,000 deaths annually [1]. Immunological studies in
humans and mice have identified parasite-specific antibodies as critical for Plasmodium control
and parasite clearance [2]. However, an abundance of data show that antibody responses gen-
erated against Plasmodium parasites are relatively short-lived and dominated by antibodies of
low affinity [3–6], which leaves individuals susceptible to repeated infection [2, 7]. Despite
these long-standing observations, the infection-induced,host-specific factors that limit the
acquisition of long-lived anti-Plasmodium antibody responses following single or repeated
Plasmodium infection remain poorly defined.
T follicular helper (Tfh) cells are essential for the generation of memory B cells and plasma
cells that produce high-affinity antibodies, two B cell subsets that comprise long-lived humoral
immunity against pathogen reinfection [8, 9]. Tfh cells functionally orchestrate germinal center
(GC) B cell reactions through ligand-receptor interactions and cytokine secretion [10]. The
importance of Tfh cells in promoting antibody-mediated control of numerous acute and
chronic infections is well established [10–12]. However, less is known about Plasmodium-spe-
cific Tfh cell differentiation, maintenance, and function, despite the critical role of Plasmo-
dium-specific secreted antibodies in limiting disease severity and promoting parasite clearance.
Indeed, numerically or functionally skewed pathogen-specificTfh responses represent an
emerging hypothesis to explain the defects or delays in the acquisition of antibody-mediated
immunity following infection [13].
In support of this hypothesis, a recent survey of Tfh cell responses in Plasmodium falcipa-
rum-exposed children revealed that a phenotypically and functionally distinct T helper 1
(Th1)-like Tfh cell subset (CXCR3+ CXCR5+PD-1+) is preferentially expanded during human
malaria [14]. Strikingly, these Th1-like Tfh cells exhibit a markedly reduced capacity to provide
B cell help in vitro and the expansion of this subset was further linked to Th1-associated, Plas-
modium infection-induced inflammation [14]. In agreement with the later observation,we
originally reported that excessive type II IFN (IFN-γ-associated inflammation impairs Tfh
activity and humoral immunity during experimentalmalaria [15], a finding recently confirmed
by others [16]. Together, these data support that Tfh responses generated during malaria may
be suboptimal, and that the inflammatory environment or cytokinemilieu induced by Plasmo-
dium blood-stage infection can impact the quantity or quality of anti-Plasmodium Tfh cell
responses with subsequent impacts on humoral immunity.
In addition to Th1-associated inflammation and systemic production of IFN-γ, type I inter-
ferons (IFNα/β) are also highly induced during human and experimental blood-stage Plasmo-
dium infection [17–22]. Type I IFNs are pleiotropic cytokines with reported variable effects on
Tfh development and function.During acute viral infection, type I IFNs suppress the Tfh
developmental program [23]. On the other hand, in vitro studies show STAT1-dependent, type
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I IFN receptor (IFNAR) signaling can promote Tfh cell differentiation [24]. To date, the func-
tional roles of type I IFNs during Plasmodium infection have mainly focused on acutely lethal,
experimental cerebral malaria (ECM) models. In this context, IFNAR signaling suppressed
Th1 development and activity, which led to elevated parasite burdens and exacerbated malaria-
induced neurological disease [17, 25]. However, the contribution of type I IFNs in regulating
Plasmodium-specific Th1 and/or Tfh activity and parasite-specific antibody responses during
non-lethal experimentalmalaria have not been extensively investigated.
Here we used complementary genetic and biochemical approaches to test the hypothesis
that IFNAR signaling represents an additional inflammatory signaling cascade that limits the
quantity and quality of Plasmodium-specific Tfh cell responses and the subsequent generation
of protective humoral immunity. Using both chronic viral and parasitic infectionmodels, we
uncovered a molecular circuit in which type I IFNs directly induce Blimp-1 expression in path-
ogen-specificCD4 T cells and promote T regulatory 1 responses. Furthermore, we identified
that type I IFN-mediated induction of Tr1- associated cytokines IL-10 and IFN-γ collaborate
to limit the generation of protective humoral immunity during experimentalmalaria.
Results
Type I IFNs limit parasite control, germinal center B cell and secreted
antibody responses during experimental Plasmodium infection
To begin to dissect the biological effects of type I IFNs during Plasmodium blood-stage infection
[17–22], we employed reagents to block IFNAR signaling in a model of non-lethal experimental
P. yoelii malaria. We administered to P. yoelii-infected mice either an irrelevant rat IgG (clone
MOPC) or an extensively characterizedmonoclonal antibody (mAb, clone MAR-15A3) that
blocks signaling from the type I IFN receptor (IFNAR) [26–28] (Fig 1A). Blocking IFNAR sig-
naling through day 4 p.i. resulted in a 25–50% decrease in P. yoelii parasitema after day 16 p.i.
(Fig 1B). By contrast, blocking IFNAR signaling during the second week of infection (day 10, 12,
14 p.i.) had no impact on parasite control (S1A Fig). These data demonstrate that early type I
IFN responses impede parasite control during experimental Plasmodium blood-stage infection.
Notably, blocking IFNAR signaling through day 4 p.i. largely did not impact parasite repli-
cation until the second week of infection (Fig 1B), which is consistent with our hypothesis that
type I IFNs negatively impact the development of humoral immunity. Thus, we next examined
the magnitude and kinetics of Plasmodium infection-inducedGC B cell responses in MOPC-
and α-IFNAR-treated mice. By the third week of experimentalmalaria, α-IFNAR treatment
resulted in 2 to 4-fold increases in the number of P. yoelii infection-induced (S1B Fig) splenic
GL7+CD95+ CD19+ GC B cells (Fig 1C and 1D). IFNAR signaling blockade was also associated
with enhanced class-switching in GC B cells (Fig 1E and 1F). The quantitative and qualitative
changes in responding B cells in α-IFNAR-treated mice were additionally linked to 2-fold
higher serum titers of T cell-dependent,merozoite surface protein 1 (MSP119)-specific anti-
body (Fig 1G). Collectively, these results show that early type I IFN signaling negatively regu-
lates parasite control and the quantity and quality of humoral immunity during experimental
Plasmodium infection.
Type I IFNs limit CD4+ T follicular helper cell accumulation and promote
T regulatory 1 responses during experimental malaria
IFNAR signaling is reported to regulate the proliferation, survival and differentiation of multi-
ple effector subsets [29], including T follicular helper (Tfh) cell responses in vitro [24] and in
vivo following immunization with model antigens [30]. Type I IFNs have also been shown to
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Fig 1. Blockade of IFNAR signaling improves parasite control and enhances humoral immunity during P. yoelli infection. (A) Experimental
design. Mice were administered either MOPC (isotype) or α-IFNAR antibodies at the indicated time points and were infected with 106 P. yoelii infected
red blood cells (pRBCs). (B) Parasitemia (% of RBCs infected) kinetics (left) and cumulative data from 4 independent experiments displaying
parasitemia on day 21 p.i. (right). (C) Representative flow plots from MOPC (top) or α-IFNAR-treated mice (bottom) depicting the proportion of
CD95+GL7+CD19+ splenic germinal center (GC) B cells on day 25 p.i. (D) Summary kinetics displaying the total numbers of GC B cells. (E,F)
Representative flow plots (E) and summary data (F) showing the proportion of class-switched (IgD-IgM-) GC B cells (G) Summary graphs displaying
the relative titers of MSP119-specific total IgG (left) and IgG2b (right) on day 25 p.i. Data (Mean +/- SEM) in (B,D,F,G) are pooled from 2–3
independent experiments per time point (3–5 mice/group for each experiment) and were analyzed using Mann-Whitney (non-parametric) tests of
statistical significance. Data in (B-G) are representative of >3 independent experiments. *P<0.05, #P = 0.05.
doi:10.1371/journal.ppat.1005945.g001
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indirectly regulate Th1 CD4 T cell activity during acutely lethal experimental cerebral malaria
and acute virus infection [25, 27, 28]. Thus, we next explored whether IFNAR signaling block-
ade differentially impacts the differentiation of Tfh or Th1 cells during prolonged P. yoelii
blood stage malaria. Of note, the total Plasmodium infection-inducedeffector CD4 T cell com-
partment can be distinguished from irrelevant (naïve) CD4 T cells via published surrogate
marker approaches that monitor conformational changes in CD11a and upregulation of CD44
on CD4 T cells following infection or vaccination [15, 31–36]. Consistent with enhanced
humoral immunity, we found α-IFNAR treatment resulted in 2 to 3-fold expansions in the fre-
quency and total number of Plasmodium-infection-induced (S1C Fig) splenic PD-
1+CXCR5+Bcl-6+ Tfh cells (Fig 2A–2D). We also observedqualitative changes in the Tfh com-
partment following IFNAR signaling blockade, including a 25% increase in Tfh expression of
ICOS (Fig 2C and 2E), a co-stimulatory molecule that is essential for Tfh commitment, migra-
tion and function [37, 38]. These data support that Plasmodium infection-induced type I IFNs
limit Tfh accumulation.
In addition to alterations in the Tfh compartment, α-IFNAR treatment also resulted in 20%
decreases in both the amount of CD4 T cell-expressed T-bet and the proportion of T-bet+ Th1
effector CD4 T cells, compared to control MOPC treatment (Fig 2F and 2G). Notably, ectopic
expression of T-bet can induce expression of Blimp-1 (34), a transcriptional repressor that reg-
ulates terminal differentiation of effector T cells (35) and limits Tfh and T cell effector function
(36). Moreover, pathogen-specificT-bet+ effector CD4 T cells responding to prolonged or
chronic infections often co-express Blimp-1 (37) and are functionally categorized as T regula-
tory 1 (Tr1) CD4 T cells. Thus, we further reasoned that type I IFNs also promote the expan-
sion or accumulation of T-bet+Blimp-1+ Tr1 cells during experimentalmalaria. To formally
test this, we infected Blimp-1-eYFP reporter mice with P. yoelii and examined the kinetics of
simultaneous T-bet and Blimp-1-eYFP expression in Plasmodium infection-induced (S2A Fig)
effector CD4 T cells. We found that ~50% of T-bet+ effector CD4 T cells co-expressed Blimp-
1-eYFP in both MOPC-control and α-IFNAR-treated mice (Fig 2F). Notably, α-IFNAR treat-
ment reduced the proportion and number of infection-induced effector CD4 T cells co-
expressing both T-bet and Blimp-1-eYFP by>30% (Fig 2H–2J). Moreover, compared to effec-
tor CD4 T cells recovered from MOPC-treated mice, expression of Blimp-1-eYFP signal was
reduced by>30% on days 8 and 16 p.i. in Plasmodium infection-inducedeffector CD4 T cells
recovered from α-IFNAR-treated mice (Fig 2K).
To gain further insight into the link between type I IFN signaling and Blimp-1 induction,
and determine whether the IFNα/β-Blimp-1 circuit is unique to Plasmodium infection, we next
initiated comparative studies using mice infected with LCMV clone 13, which also triggers a
highly inflammatory, Th1-biased response. On day 14 p.i., total virus infection-induced
(CD44hiCD11ahi) and epitope-specific (GP61-80) effector CD4 T cells showed marked reduc-
tions in both the proportion of Blimp-1-eYFP+ cells (S2B Fig) and per-cell expression of
Blimp-1-eYFP (S2C Fig) following administration of α-IFNAR to LCMV clone 13-infected
mice. As a composite, these data show that type I IFNs suppress the development or accumula-
tion of Tfh cells and promote the expansion of T-bet+Blimp-1+ effector CD4 T cells during
blood stage Plasmodium infection and that the IFNα/β-Blimp-1 circuit is a generalizable fea-
ture of systemic, Th1-biased infections.
Type I IFN signaling promotes the development and function of T
regulatory 1 cells during experimental malaria
To explore the biological consequences of reduced CD4 T cell co-expression of T-bet and
Blimp-1 following α-IFNAR treatment we next examined cytokine production by Plasmodium
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Fig 2. Blockade of IFNAR signaling enhances Tfh cell accumulation and limits T regulatory 1 responses during
experimental malaria. (A-K) Wild type (WT) mice were administered either MOPC or α-IFNAR antibodies and were infected
with 106 pRBCs. (A) Representative flow plots from day 25 p.i. depicting the percentage of CXCR5+PD-1+ Tfh cells among
splenic CD44+ CD4 T cells from MOPC and α-IFNAR-treated mice. (B) Summary kinetics displaying the proportion (left) and
total number (right) of Tfh cells from MOPC and α-IFNAR-treated mice. Representative flow plots (C) and summary data
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infection-inducedeffector CD4+ Tr1 cells. Tr1 cells simultaneously express T-bet, Blimp-1,
IFN-γ and IL-10 during chronic viral and protozoan infections and have been shown to sharply
limit pathogen control [39–41]. Moreover, Foxp3-negative Tr1 CD4 T cells are the major
source of IL-10 in these scenarios [39, 42], and Tr1 activity and expression of IL-10 is Blimp-
1-dependent [42–44]. As predicted, co-expression of IFN-γ and IL-10 was largely restricted to
Blimp-1-eYFP+ Plasmodium infection-induced effector CD4 T cells (Fig 3A), and α-IFNAR
treatment significantly decreased the frequency and number of Blimp-1-eYFP+ IFN-γ+IL-10+
effector cells on day 8 p.i. (Fig 3A–3C) and the amount of IL-10 expressed per cell (Fig 3D).
Consistent with alterations in T-bet+Blimp-1-eYFP+ Tr1 numbers (Fig 2J) and cytokine
expression, we also observed3-4-fold reductions in serum IL-10 levels and 2-fold reductions in
serum IFN-γ between days 8–16 p.i. in α-IFNAR-treated Plasmodium-infected mice compared
to MOPC-treated mice (Fig 3E and 3F). Of note, simultaneous expression of CD49b and LAG-
3 is reported to identify Tr1 cells in both mice and humans [45]. Although the majority
(>70%) of Plasmodium infection-inducedBlimp-1-eYFP cells expressed LAG-3 (S3A and S3B
Fig), CD49b expression was largely restricted to NK cells (S3C Fig). Collectively, these data
show that early, Plasmodium-induced type I IFNs promote the development of effector Tr1
responses and Tr1 co-expression of IL-10 and IFN-γ during experimentalmalaria.
IFN-γ and IL-10 collaborate to limit Tfh accumulation, humoral immunity
and parasite control during Plasmodium blood-stage infection
Excessive IFN-γ production by T cells limits Tfh and GC B cell activity and constrains anti-
Plasmodium humoral immunity [15], supporting that IFN-γ can negatively regulate Tfh func-
tion. However, whether IL-10 can additionally or independently inhibit Tfh responses during
Plasmodium infection has not been addressed. Indeed, the consistent improvements in parasite
control and humoral immunity (Fig 1) and marked reductions in circulating serum and
Tr1-expressed IL-10 and IFN-γ (Fig 3) following α-IFNAR treatment raised the possibility that
together these cytokinesmay limit Tfh responses and humoral immunity during Plasmodium
infection. In support of this notion, both serum IFN-γ [15] and IL-10 levels in experimental
mice strongly and inversely correlated with the magnitude of the Tfh response on day 16 p.i
(Fig 4A). Becauseα-IFNAR treatment significantly reduced the number of IL-10+IFN-γ+ Plas-
modium infection-inducedTr1 cells and serum IFN-γ and IL-10 levels, we hypothesized that
combinatorial IL-10R signaling blockade and IFN-γ neutralization would phenocopy α-
IFNAR treatment, resulting in increased Tfh accumulation, improved humoral immunity, and
enhanced parasite control during experimentalmalaria. We found that simultaneously block-
ing the activity of these Tr1-derived cytokines potently enhanced parasite control (Fig 4B),
which was associated with expanded numbers of ICOS+ Tfh cells (Fig 4C–4E). Of note, GC B
cell reactions were not significantly elevated by day 14 p.i. following simultaneous
depicting total numbers of CXCR5+PD-1+Bcl-6+ Tfh (D) and ICOS (E) expression (geometric MFI) on Tfh cells from MOPC and
α-IFNAR-treated mice on day 16 p.i. (F-K) Blimp-1-eYFP reporter mice were administered either MOPC or α-IFNAR antibodies
and were infected with 106 pRBCs. (F) Representative dot plots (left) depicting the proportion of splenic CD44+CD11ahi CD4 T
cells in MOPC and α-IFNAR-treated mice expressing either T-bet (middle) or Blimp-1-eYFP in T-bet+ CD4 T cells (right). (G)
Summary kinetics depicting the relative expression of T-bet (gMFI) among Plasmodium infection-induced CD44+CD11a+ CD4
T cells. (H) Representative flow plots from MOPC and α-IFNAR-treated mice on day 8 p.i showing the proportion of splenic
CD44+CD11ahi CD4 T cells simultaneously expressing both T-bet and Blimp-1-eYFP. (I-J) Summary kinetics depicting the
frequency (I) and total number (J) of T-bet+Blimp1-eYFP+ splenic CD44+CD11ahi CD4 T cells in MOPC and α-IFNAR-treated
mice. (K) Summary kinetics of Blimp-1-eYFP expression (gMFI) in splenic CD44+CD11ahi CD4 T cells in MOPC and α-IFNAR-
treated mice. Data (Mean +/- SEM) in (A,D,G,J-K) are pooled from 2–3 independent experiments per time point (3–5 mice/
group for each time point) and were analyzed using Mann-Whitney (non-parametric) tests of statistical significance. N.S. = not
statistically significant. *P<0.05, **P<0.01.
doi:10.1371/journal.ppat.1005945.g002
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Fig 3. Type I interferons promote co-production of IFN-γ and IL-10 by Plasmodium infection-induced Tr1 cells. (A-F) Blimp-
1-eYFP reporter mice were administered either MOPC or α-IFNAR antibodies and were infected with 106 pRBCs. (A)
Representative flow plots depicting the frequency of Blimp-1-eYFP expression and subsequent IFN-γ and IL-10 cytokine production
in Blimp-1-eYFP- and Blimp-1-eYFP+ splenic CD44+CD11ahi CD4 T cells from MOPC and α-IFNAR-treated mice after ex vivo
stimulation with PMA/Ionomycin. (B) Summary data displaying the proportion of Blimp-1-eYFP- and Blimp-1-eYFP+ effector
CD44+CD11ahi CD4 T cells that are positive for either IFN-γ+ (left) or IL-10+ (right) after ex vivo stimulation. (C) Summary data
displaying the proportion (left) and total number (right) of IFN-γ+ IL-10+ cells among Blimp-1-eYFP- and Blimp-1-eYFP+ Plasmodium
infection-induced CD4 T cells from MOPC and α-IFNAR-treated mice on day 8 p.i. (D) Summary data showing the gMFI of IL-10 in
Plasmodium infection-induced CD4 T cells on day 8 p.i. (E-F) Summary data (Mean +/- SEM) showing the levels of circulating IL-10
(E) and IFN-γ (F) in sera from MOPC and α-IFNAR-treated mice. Data (Mean +/- SEM) in (B-F) are pooled from 2–3 independent
experiments (3–4 mice/group per experiment) and were analyzed using Mann-Whitney non-parametric tests. Data in (A-F) are
representative of 3 independent experiments. N.S. = not statistically significant.
doi:10.1371/journal.ppat.1005945.g003
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neutralization of IFN-γ and blockade of IL-10 signaling (S4A and S4B Fig), consistent with
marginally altered GC B cell responses following α-IFNAR treatment at this early time point
(Fig 1D) Nevertheless, combined targeting of both IFN-γ and IL-10 elevated titers of parasite-
specific secreted antibody by day 14 p.i. (Fig 4F). Solely blocking IL-10 signaling transiently
limited parasite replication (Fig 4B), but parasite control was eventually lost after day 14 p.i.,
which was associated with reduced GC B cell reactions (S4A and S4B Fig) and diminished
secretion of parasite-specific antibody (Fig 4F). These data support that IL-10 insulates the
host against the reported pathological effects of excess IFN-γ [15, 16, 43]. While neutralization
of IFN-γmodestly enhanced GC B cell frequencies (S4B Fig), parasite control was also eventu-
ally impaired (Fig 4B). Indeed, improvements in both anti-Plasmodium humoral immunity
and parasite control only occurred following simultaneous neutralization of IFN-γ and block-
ade of IL-10 signaling. As a composite, our data support that a primary effect of Plasmodium
infection-induced type I IFN is the expansion of effector Tr1 cells and that Tr1-associated
Fig 4. IFN-γ and IL-10 cooperate to limit Tfh accumulation and secreted antibody responses during Plasmodium blood-stage infection.
(A) Negative correlation between levels of circulating IL-10 and the total number of splenic Tfh cells in MOPC and α-IFNAR-treated mice on day 16
p.i. Data were analyzed using linear regression. (B-F) Groups of mice (n = 5/group) were treated with either rIgG, α-IL-10R, α-IFN-γ, or α-IFN-γ+α-
IL-10R. (B) Parasitemia kinetics. Statistical results for comparisons between rIgG- and α-IFN-γ+α-IL-10R-treated mice are displayed. Data were
analyzed using Mann-Whitney non-parametric tests. (C) Representative flow plots depicting the proportion of PD-1+CXCR5+ Tfh cells among
CD44hi splenic CD4+ T cells in rIgG-, α-IL-10R-, α-IFN-γ or α-IFN-γ+α-IL-10R-treated mice. (D) Summary data showing the total number of splenic
Tfh cells in rIgG-, α-IL-10R-, or α-IFN-γ+α-IL-10R-treated mice on day 14 p.i. (E) Summary data showing ICOS expression (gMFI) on Tfh cells from
rIgG-, α-IL-10R-, α-IFN-γ or α-IFN-γ+α-IL-10R-treated mice. (F) Summary graph displaying the relative serum titers of MSP119-specific total IgG in
rIgG-, α-IL-10R-, α-IFN-γ, or α-IFN-γ+α-IL-10R-treated mice on d14 p.i. Statistical results for comparisons between rIgG- and α-IFN-γ+α-IL-10R-
treated mice are displayed and data were analyzed using Mann-Whitney non-parametric tests. Summary data (Mean +/- SEM) in (D-E) were
analyzed using Kruskal-Wallis non-parametric tests. Data in (B-F) are representative of two independent experiments (5 mice/group per
experiment). N.S. = not statistically significant. *P<0.05, ***P<0.0001.
doi:10.1371/journal.ppat.1005945.g004
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cytokines IL-10 and IFN-γ act together to limit Tfh accumulation, anti-malarial humoral
immunity and parasite control via release of IL-10 and IFN-γ.
Type I IFNs directly induce T-bet and Blimp-1 and co-expression of IL-
10 and IFN-γ in Plasmodium infection-induced effector CD4 T cells
during Plasmodium blood-stage infection
Our data show that neutralizing either type I IFN or Tr1 effector cytokines IFN-γ and IL-10
promotes the expansion of Tfh cells and enhances humoral immunity and parasite control.
However, to formally test whether type I IFN-mediated suppression of Tfh accumulation and/
or induction of the T-bet-Blimp-1 axis in responding CD4 T cells is CD4 T cell-intrinsic, we
seeded naive tcrα-/- mice with equivalent numbers of naïve, congenically marked wild type
(WT) and ifnar1-/- CD4 T cells one day before P. yoelii challenge (Fig 5A). At defined intervals
after challenge, we assessed Tfh Bcl-6 expression, as well as T-bet and Blimp-1 co-expression
in effector WT and ifnar1-/- CD4 T cells recovered from the same host. Although ifnar1-/- CD4
T cells did not expand or accumulate to the same degree as WT CD4 T cells (S5A and S5B Fig)
we found no difference in the proportion of WT and ifnar1-/- donor-derived cells that adopted
the canonical CXCR5+PD-1hiBcl-6+ Tfh phenotype (S5A–S5D Fig), suggesting that direct
IFNAR signaling on CD4 T cells does not intrinsically impair Tfh differentiation during experi-
mental malaria. In line with this, expression of IFNAR was negligible on effector Tfh cells,
compared to effector Th1/Tr1 effector CD4 T cells (not depicted). Decoupling of IFNAR sig-
naling in expanding Tfh cells would also be consistent with reports showing that Tfh cells
become refractory to specific cytokine signaling networks very early after their initial priming
[46]. By contrast, we found markedly lower proportions of T-bet+Blimp-1+ ifnar1-/- CD4 T
cells (Fig 5B and 5C), as well as 20–40% less T-bet and Blimp-1 in ifnar1-/- CD4 T cells, com-
pared to WT CD4 T cells (Fig 5D and 5E). Notably, the proportionate decreases in T-bet and
Blimp-1 expression in ifnar-/- CD4 T cells mirror those observed following anti-IFNAR-treat-
ment (Fig 2H and 2I) and co-adoptive transfer studies also revealed sharp reductions in IFN-γ,
and IL-10 expression by ifnar1-/- effector CD4 T cells, compared to WT CD4 T cells recovered
from the same host (Fig 5F–5I), confirming that the impact of IFNα/β signaling on IL-10 and
IFN-γ expression are CD4 T cell-intrinsic. These data support that type I IFN-mediated
induction of the Tr1 program during experimentalmalaria is primarily regulated by CD4 T
cell-intrinsic IFNAR signaling. To determine the impact of CD4 T cell-intrinsic ifnar1-defi-
ciency on anti-Plasmodium humoral immunity, we undertook two complementary chimeric
approaches. First, transfer of WT or ifnar1-/- naïve CD4 T cells into separate groups of tcrα-/-
mice (e.g. Fig 5A) revealed that both Plasmodium infection-inducedGC B cell responses and
parasite control were significantly enhanced in mice seededwith ifnar1-/- CD4 T cells (Fig 5J
and 5K). Second, and consistent with our chimeric transfer studies, infection of mixed bone
marrow chimeras in which ifnar1 deficiencywas restricted to the T cell compartment (Fig 5L)
revealed 2-fold greater parasite-specific secreted IgG (Fig 5M), as well as elevated Tfh (Fig 5N
and S5E Fig), and GC B cell responses (S5F and S5G Fig). Collectively, these data support that
type I IFNs indirectly limit the accumulation of Plasmodium-specific Tfh cells and impede
humoral immunity and parasite control during experimentalmalaria via the activity of Tr1
effector cytokines.Mechanistically, although Plasmodium infection-induced type I IFNs
have no appreciable direct effects on modulating Bcl-6+ Tfh development during malaria,
they directly promote the accumulation and function of Plasmodium infection-induced
T-bet+Blimp-1+ Tr1 cells that limit humoral immunity and parasite control via secretion of
effector cytokines IL-10 and IFN-γ.
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Fig 5. CD4 T cell intrinsic IFNAR signaling limits humoral immunity and parasite control via induction of Tr1 cell expression of
T-bet and Blimp-1 and co-production of IFN-γ and IL-10. (A) Experimental design. Tcrα-/- mice were seeded with equivalent numbers
of CD45.1/2 WT and CD45.2/2 (ifnar1-/-) naïve CD4 T cells and infected with 106 pRBCs one day post-transfer. Cellular reactions were
analyzed 2 weeks p.i. (B) Representative flow plots showing the proportion of WT and ifnar1-/- cells among recovered activated CD44hi
CD4+ T cells and their simultaneous expression of T-bet by Blimp-1 on day 14 p.i. (C) Summary graph depicting the proportion of activated
Type I IFNs Limit Humoral Immunity
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Type I IFN induction of Blimp-1 can occur independently of IL-2
signaling
CD4 T cell-intrinsic IFNAR signaling can induce expression of the high-affinity IL-2 receptor
(CD25), sensitizing CD4 T cells to IL-2 signaling [47] and activation of STAT5 [23] a known
inducer of prdm1, which encodes for Blimp-1. To begin to explore the mechanistic role of IL-2
in the IFNα/β-Blimp-1 circuit, we examined the expression kinetics of CD25 on Plasmodium
infection-inducedand LCMV GP61-80-specific CD4 T cells in MOPC- and α-IFNAR-treated
Plasmodium parasite- or virus-infectedmice, respectively. We found that α-IFNAR treatment
significantly reduced CD25 expression on CD4 T cells responding to either Plasmodium (Fig
6A and 6B) or LCMV clone 13 infection (S6A and S6B Fig). Notably, reduced Blimp-1 expres-
sion in co-transferred ifnar1-/- CD4 T cells (Fig 5B–5D) also correlated with a 30% decrease in
CD25 surface expression compared to WT effector CD4 T cells on day 4 p.i. (Fig 6C), suggest-
ing that type I IFNs may function to elevate or sustain CD25 expression, thereby enhancing
STAT5 activity and Blimp-1 induction. To formally test this, we next performed in vitro CD4
T cell culture experiments.We observeddose-dependent effects of exogenous IFNβ-mediated
phosphatidylinositol 3-kinase (PI3K) activation and Blimp-1 induction, as measured by CD98
expression [48] and Blimp-1-eYFP expression, respectively, in CD4 T cells (Fig 6D and 6E).
Strikingly, IFNβ-mediated induction of Blimp-1 and PI3K activation occurred even when IL-2
was neutralized (Fig 6D and 6E). These results support that type I IFNs may directly induce
Blimp-1 expression in CD4 T cells independently of IL-2 signaling, likely via activation of the
PI3K pathway. Collectively, our results show that CD4 T cell intrinsic type I IFN signaling
directly induces T-bet and Blimp-1 expression in Plasmodium infection-inducedeffector CD4
T cells, thereby promoting Tr1 cell development and function.Moreover, Tr1 effector cyto-
kines IL-10 and IFN-γ collaborate to suppress Tfh accumulation, anti-Plasmodium humoral
immunity, and parasite control.
Discussion
The importance of IL-10-secreting Tr1 cells in limiting immunopathology during highly
inflammatory Th1-biased infection is well appreciated [40, 41, 43, 49]. However, the pathways
that induce or support Tr1 differentiation are not well understood.Here we show that early
type I IFN responses during inflammatory Th1-biased infections promote the differentiation
of T-bet+Blimp-1+ Tr1 cells and limit humoral immunity and parasite control during experi-
mental malaria. Mechanistically, we identified that type I IFNs directly induce T-bet and
Blimp-1 expression in CD4 T cells responding to Plasmodium blood-stage infection, which
amplifies their production of IL-10 and IFN-γ. Furthermore, we show that these two Tr1-asso-
ciated cytokines collaborate to suppress humoral immunity and parasite control.
Multiple reports show that type I IFNs are highly induced during malaria, yet the extent to
which they regulate anti-Plasmodium immunity or disease is often conflicting.Clinical studies
WT and ifnar1-/- CD4 T cells simultaneously expressing both T-bet and Blimp-1. (D-E) Summary graphs displaying the relative expression
(gMFI) of Blimp-1 (D) and T-bet (E) in activated WT and ifnar1-/- CD4 T cells. (F) Representative flow plots depicting the proportion of
activated WT and ifnar1-/- CD4 T cells competent to produce IFN-γ and IL-10 after ex vivo stimulation. (G-I) Summary data displaying the
frequency of activated WT and ifnar1-/- CD4 T cells producing either IFN-γ (G) or IL-10 (H) on day 14 p.i. after ex vivo stimulation. (J-K)
Separate groups of tcrα-/- mice were seeded with equivalent numbers of WT (CD45.1/2) and ifnar1-/- (CD45.2/2) naïve CD4 T cells and
infected with 106 pRBCs once day post-transfer. Parasite burdens and cellular reactions were analyzed on day 16 p.i. (L) Experimental
design for generating mixed bone marrow chimeras in which the T cell compartment is either WT (TWT) or ifnar-deficient (Tifnar-/-). (M)
Secreted parasite-specific IgG was evaluated by ELISA in chimeric mice on day 23 p.i.. (N) Summary data depicting the total number of
Tfh cells in chimeric mice. Data (Mean +/- SD) in (C-E, G-I, and M,N) were analyzed using Mann-Whitney non-parametric tests and are
representative of two independent experiments with 5 mice per group per experiment. Data (Mean +/- SEM) in (J,K) were pooled from two
independent experiments with 3–4 mice/group per experiment and were analyzed using Mann-Whitney non-parametric tests.
doi:10.1371/journal.ppat.1005945.g005
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show that specific SNPs in the gene encoding ifnar1 are associated with resistance to cerebral
malaria [50], and case-control studies in Angolian children and neuro-malaria patients in
Thailand support that type I IFN responses are either associated with the development of cere-
bral malaria [51] or precede the induction of IFN-γ expression and severe disease [20]. These
latter studies are consistent with our experiments showing that blocking type I IFN signaling
during non-lethal experimentalmalaria abrogates the development of IFN-γ+T-bet+ Th1
responses. Similarly, multiple reports show that ifnar1-/- mice have altered Th1 activity and are
largely resistant to the development of acutely lethal P. berghei-induced experimental cerebral
Fig 6. Type I IFN-mediated induction of Blimp-1 in CD4 T cells can occur independently of IL-2 signaling. (A-B)
Blimp-1 reporter mice were administered either MOPC or α-IFNAR antibodies and were infected with either106 pRBCs.
(A) Representative flow plots depicting the expression of CD25 on Plasmodium infection-induced effector CD4 T cells
from MOPC and α-IFNAR-treated mice on day 8 p.i. (B) Cumulative data showing surface CD25 expression (gMFI) on
Plasmodium infection-induced splenic CD44hiCD11ahi CD4+ T cells. Data (Mean +/- SEM) in (B) are pooled from 2
independent experiments (3–4 mice/group). (C) Summary data (Mean +/- SD) showing CD25 expression (gMFI) on WT
and ifnar1-/- CD4 T cells recovered from tcrα-/- on day 4 post-Plasmodium infection. Data in (B,C) were analyzed using
Mann-Whitney non-parametric tests of statistical significance. (D,E) Naïve CD4 T cells from Blimp-1-eYFP reporter mice
were stimulated with α-CD3/α-CD28 and treated with or without rIFNβ or anti-IL-2 blocking antibodies. (D) Summary
data (Mean +/- SD) depicting surface expression of PI3K-dependent CD98 on CD44hi CD4+ T cells cultured under the
various treatment conditions. (E) Summary data (Mean +/- SEM) showing Blimp-1-eYFP expression (gMFI) in CD44hi
CD4+ T cells under the various treatment conditions. Data in (E) are normalized to Blimp-1 expression (MFI) in non-
stimulated CD4 T cells and are pooled from 3 independent experiments. Data in (D,E) are representative of 3
independent experiments and were analyzed using Kruskal-Wallis non-parametric tests of statistical significance. N.S. =
not statistically significant. *P<0.05, **P<0.01.
doi:10.1371/journal.ppat.1005945.g006
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malaria (ECM) [17, 21, 25, 52]. In contrast, following infectionwith non-lethal P. yoelii or P.
chabaudi spp., ifnar1-/- mice exhibit either exacerbated disease and higher parasite burdens
[22, 53] or no phenotype at all [18]. Although most studies have focused on the role of type I
IFN signaling in either regulating myeloid dendritic cell stimulatory potential or Plasmodium
parasite control during the first week of acute infection, to our knowledge no studies have
examined whether type I IFN responses regulate humoral immunity during Plasmodium infec-
tion. To address this question, and to avoid pitfalls associated with altered immune system
development or dysregulated hematopoiesis in ifnar1-/- mice [54, 55], we employed transient
blockade of type I IFN responses and chimeric/genetic approaches to evaluate CD4 T cell
intrinsic and extrinsic roles for type I IFN signaling during experimentalmalaria. We found
that IFNAR signaling blockade during experimentalmalaria enhanced the quantity and quality
of the Tfh cell response, bolstered the magnitude of the germinal center reaction and elevated
titers of parasite-specific antibody against MSP119, all of which were associated with improved
control over parasite replication. Our chimeric studies show that type I IFN-mediated suppres-
sion of Tfh accumulation and humoral immunity is indirect.
During chronic LCMV infection, blocking type I IFN signaling, primarily the activity of
IFNβ [56], enhances CD4 T cell function and accelerates resolution of persistent infection [27,
28]. However, the two arms of the adaptive immune response primarily responsible for limiting
virus persistence and promoting resolution of LCMV, cytotoxic CD8 T cells and Tfh-depen-
dent antibody responses, were not quantitatively or qualitatively enhanced [27, 28]. By com-
parison, during acute LCMV infection, type I IFNs are purported to directly inhibit Tfh cell
differentiation via up-regulation of CD25, which sensitizes CD4 T cells to IL-2 signaling and
promotes STAT5 binding to the Bcl-6 promoter, thereby blocking the Tfh-promoting activity
of STAT3 [23]. Of note, administration of recombinant IFNβ during in vitro activation of
naïve CD4 T cells induced CXCR5 and Bcl-6 expression in WT but not ifnar1-/- CD4 T cells
(not depicted and [24], highlighting that type I IFNs may positively regulate molecules impor-
tant for the Tfh cell program in vitro. Thus, we examined possible CD4 T cell-intrinsic impacts
of type I IFN signaling during experimentalmalaria. To do this, we performed co-adoptive
transfer studies of WT and ifnar1-/- CD4 T cells into Plasmodium infectedmice, because analy-
ses of humoral immunity and parasite control in tcrα-/- mice seededwith either WT or ifnar1-/-
cells may be confounded by the markedly reduced proliferation of CD4 T cells lacking the type
I IFN receptor (e.g. Fig 5C). We found ifnar1-/- and WT CD4 T cells differentiated into Tfh
cells in equal proportions, despite reduced CD25 expression on ifnar1-/- CD4 T cells. These
data suggest that neither CD4 T cell-intrinsic type I IFN signaling nor IFN-mediated upregula-
tion of CD25 directly limits Tfh development during experimentalmalaria. Instead, our data
show that Plasmodium infection-induced type I IFNs promote the differentiation and function
of T-bet+Blimp-1+ effector CD4 T cells. Pathogen-specific effector CD4 T cells are the major
source of IL-10 following prolonged viral and parasitic infection.We found that IL-10 and
IFN-γ expression were largely restricted to Blimp-1+ Tr1 cells, compared to all other Plasmo-
dium infection-induced effector CD4 T cell subsets. Moreover, we identified that the effector
cytokines of Tr1 cells, IL-10 and IFN-γ, constrain Tfh accumulation and protective humoral
immunity. Our data supporting IL-2-independent induction of Blimp-1 during Plasmodium
infection is also consistent with a recent report showing that IL-2 blockade failed to modulate
Blimp-1 expression in LCMV-specific CD4 T cells [42].
Excessive Th1 activity and secretion of IFN-γ can limit the development and function of
Tfh cells during malaria [15, 16, 57]. As noted, type I IFNs can increase CD4 T cell responsive-
ness to IL-2 signaling, which can stimulate STAT5 activation and skew CD4 T cells towards
Th1 lineage commitment. Alternatively, in vitro studies show that type I IFNs can activate
STAT4-mediated induction of T-bet and Th1 activity [24]. Consistent with these observations,
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we found that blocking type I IFN signaling during experimentalmalaria reduced T-bet expres-
sion in infection-inducedTh1 cells. Here we extend these data and provide in vivo evidence
that type I IFNs may directly induce T-bet to reinforce the Th1 program. Notably, ectopic
expression of T-bet in antigen-specificCD8 T cells promotes Blimp-1 expression [58]. Further-
more, several studies show that during prolonged, highly inflammatory parasitic and viral
infections, Th1 cells co-express the transcription factor Blimp-1, a transcriptional repressor
that is required for Th1/Tr-1 production of IL-10 [42–44]. Tr1 cell production of IL-10 is
known to limit pathogen control during chronic parasitic and viral infections [42, 43]. Thus,
we assessed whether type I IFNs also impact Blimp-1 expression in CD4 T cells during experi-
mental malaria or chronic LCMV infection. Strikingly, IFNAR signaling blockade decreased
Blimp-1 expression in both parasite infection induced- and virus-specificCD4 T cells. Thus,
the type I IFN-Blimp-1 axis represents a generalizable feature of prolonged/chronic pro-
inflammatory infections. Importantly, compared to WT CD4 T cells, ifnar1-/- CD4 T cells
responding to malaria also exhibited a 30% decrease in the co-expression of T-bet and Blimp-
1, demonstrating that CD4 T cell-intrinsic IFNAR signaling directly induces transcription fac-
tors important for Tr1 function. Accordingly, both antibody-mediated blockade and genetic
ablation of IFNAR signaling resulted in markedly reduced Tr1 expression of IFN-γ and IL-10.
These effects were also accompanied by reduced levels of serum IFN-γ and IL-10 in α-IFNAR-
treated mice.
The importance of Tr1 cells in limiting inflammatory-mediated immunopathology during
chronic viral and parasitic infections has been established [39, 40, 43, 59, 60]. However, Tr1
cell production of IL-10 can also hamper pathogen control [42, 43]. Defining the cellular and
molecularmechanisms that govern Tr1 cell differentiation and function is therefore of interest
and has therapeutic implications for Th1-inflammatory and autoimmune diseases, including
cancer. Previous reports have identified that the inflammatory cytokines IL-27 and IL-12 drive
Blimp-1 and IL-10 expression in both antigen-specific Tr1 and CD8 T cells. [61–63]. Further-
more, ICOS is linked to Tr1 development and activity [64], and recent studies show that sys-
temic IL-27 and ICOS cooperate to regulate Tr1 activity during experimentalmalaria [65];
however, in these reports neither IL-27R signaling nor ICOS was essential for Tr1 development
during P. yoelii malaria [65]. By contrast, we show that type I IFNs act directly on pathogen-
specific CD4 T cells to induce co-expression of T-bet and Blimp-1 and their downstream
Tr1-assocatied effectormolecules IFN-γ and IL-10. Our in vivo data are also consistent with
studies demonstrating IFNβ can trigger IL-10 production by CD4 T cells in vitro [66]. While
CD4 T cell-derived IL-2 has been linked to Blimp-1 and IL-10 expression in CD8 T cells [67],
we found that IFNβ-mediated Blimp-1 induction in in vitro stimulated CD4 T cells did not
involve IL-2 signaling. Thus, our data uncover a previously unrecognized circuit and an addi-
tional mechanism for Tr1 development in vivo during highly inflammatory, Th1-biased
infections.
One of the most striking and consistent differences between Plasmodium infection-induced
effector CD4 T cells recovered from control rIgG- and α-IFNAR-treated mice, or WT and
ifnar1-/- effector CD4 T cells following adoptive transfer, was their diminished capacity to co-
produce IL-10 and IFN-γwhen IFNAR signaling was abrogated. While excessive IFN-γ is
known to limit anti-Plasmodium humoral immunity [15, 57], only a limited number of studies
have examined the impact of IL-10 on the germinal center reaction and humoral immunity,
with variable results reported [68–72]. Although IL-10 can constrain Tfh differentiation fol-
lowing immunization [69], whether IL-10 plays a role in promoting or inhibiting Tfh cell dif-
ferentiation, maintenance or function during infection remains less clear. Notably, a recent
study identified that frequencies of IFN-γ and IL-10 co-producing CD4 T cells were increased
in Ugandan children who presented with>2 malaria episodes/year, compared to children who
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presented with<2 malaria episodes/year [73]. Although this study did not assess humoral
immunity (nor could causality be determined), these observations are consistent with Tr1
responses limiting protective immunity.
The capacity of IL-10 to modulate humoral immunity is likely multifaceted. Our data show
that blockade of IL-10R signaling abrogates humoral immunity during experimentalmalaria.
However, simultaneously blocking IL-10R signaling and neutralizing IFN-γ enhances parasite
control and parasite-specific antibody responses. IL-10 can also limit the activity and function
of antigen presenting cells (APC) [74], with potential impacts on Tfh priming. Conversely, IL-
10 can signal via STAT3, which is important for promoting Tfh development [23]. Of note, IL-
10 can also function in a feedback loop to limit the activity of effector Th1 cells during chronic
virus infection [42]. In that study, IL-10 expression was Blimp-1-dependent, and prolonged
TCR engagement and IRF4 activity were mechanistically linked to Blimp-1 induction. Our
data show that type I IFN signaling directly and additionally contributes to Blimp-1 induction
in cells responding to either Plasmodium or chronic LCMV infection, further supporting that
type IFN-mediated induction of Blimp-1 and subsequent expansion of immunosuppressive
Tr1 cells represents a generalizable feature of inflammatory Th1-biased infections.
Collectively, our results identify a previously unrecognized inhibitory circuit wherein CD4
T cell intrinsic type I IFN-signaling directly induces a T-bet-Blimp-1 axis in responding Plas-
modium infection-inducedTr1 cells, thereby promoting expression of IFN-γ and IL-10 that
cooperate to inhibit Tfh accumulation and expression of ICOS. Our data also support that
blockade of IFNAR signaling or neutralization of Tr1 effectormolecules IFN-γ and IL-10 dur-
ing malaria may bolster Plasmodium-specific Tfh responses, enhance parasite control, and pro-
mote the establishment of humoral immunity. Our report identifies additional mechanisms
that limit Plasmodium-specific antibody responses and highlights pathways that warrant con-
sideration as potential targets when designing an efficaciousmalaria vaccine or novel immu-
notherapeutics to combat malarial disease.
Materials and Methods
Ethic statement
All animal experiments were conducted in accordance with the Animal Welfare Act and the
recommendations in the Guide for the Care and Use of LaboratoryAnimals of the National
Institutes of Health. OUHSC animal facilities have full accreditation from the Association for
Assessment and Accreditation of Laboratory Animal Care and are PHS-assured (Assurance
Number: # A3165-01). All animal procedures were approved by the OUHSC Animal Care and
Use Committee (IACUC) under protocol 15–088 and the Office of Animal Welfare Assurance
(OAWA), which oversees the administration of the IACUC at OUHSC.
Mice, Plasmodium and LCMV infection, and biologics
C57BL/6 wild type, tcrα-/-, Blimp-1-eYFP reporter, ifnar1-/-, and il10rb-/- mice (6–8 weeks, 16–
21 g) were purchased from Jackson Laboratories. Plasmodium yoelii (clone 17XNL, obtained
from MR4 (ATCC)) was routinely passaged through mosquitoes and mouse infections were
initiated by serial transfer of 106 parasite-infected red blood cells via tail vein injection. LCMV
clone 13 infectionwas administered intravenously at a dose of 106 PFU. Parasitemia was mea-
sured using flow cytometry as described [75]. One day prior to P. yoelii infection,mice were
injected i.p. with either 1.5 mg of MOPC isotype control or MAR1-5A3 (α-IFNAR) monoclo-
nal antibodies, followed by 0.75 mg doses on days 2 and 4 p.i. Anti-IL-10 receptor (clone
1B1.3a), anti-IFN-γ (clone XMG1.2) were injected i.p. in 200 and 500 μg doses on days 7 and
10 p.i., respectively. All biologics were acquired from BioXcell.
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Bone marrow chimeras
For TWT and Tifnar-/- chimeras, WT recipient mice were irradiated with 6.5 and 5.5 Gy, sepa-
rated by 12 hours. Bone marrow from tcrα-/- and ifnar-/- or WT mice was mixed 1:9 and 107
cells were injected i.v. Mice were maintained on oral sulfamethoxazole for 2 weeks. Chimerism
was assessed at 6 weeks in peripheral blood using congenic markers. Chimerism in the T cell
compartment was 65–70% among 20 mice in two independent experiments.Mice were
infected with P. yoelii at 8 weeks.
Flow cytometry
Mouse splenocytes were subjected to red blood cell lysis, washed and subsequently stained
using fluorescently labeled antibodies against mouse CD4 (clone GK1.5), CD11a (clone M17/
4), CD19 (clone 6D5), CD25 (clone PC61), B220 (clone RA3-6B2), CD44 (clone IM7), CD49b
(clone DX5), CD95 (clone Jo2), CD98 (clone RL388), CD138 (clone 281–2), ICOS (clone
7E.17G9), LAG-3 (clone eBioC9B7W), PD-1 (clone RMP1-30), T and B cell activation antigen
(clone GL-7), IgD (clone 11-26c.2a), or IgM (clone RMM-1). Reagents were acquired from Bio-
legend, Tonbo, eBioscience or BD Bioscience.Mouse splenocytes from LCMV cl13-infected
mice were also stained with GP61-80 tetramer reagents (NIH) for one hour at room temperature
before performing additional surface staining. In some experiments, cells were permeabilized
with cytofix/cytoperm(BD Bioscience) followed by intracellular staining using anti-mouse IL-
10 (JES5-16E3) and anti-mouse IFN-γ, (XMG1.2; Biolegend) or anti-IL-2 (JES6-5H4;
eBioscience). For analysis of T follicular helper cells, splenocytes were incubated for 60 min at
4°C with rat anti-mouse CXCR5 (2G8; BD) and subsequently stained for 30 min at 4°C in the
presence of biotinylated goat anti-rat IgG (Jackson), followed by staining with fluorochrome-
conjugated anti-CD4, anti-CD44, anti-PD-1, and streptavidin-APC. T-bet (4B10), Bcl-6
(K112-91), and Blimp-1 (5E7), were stained after fixation and permeabilization using the
FoxP3 staining buffer set (eBioscience). Samples were acquired using a Stratedigm S1200Ex
flow cytometer and data was analyzed using FlowJo software (Tree Star, Inc., Ashland OR).
MSP119 and Cytokine ELISA
Plates (Nunc) were coated with recombinant MSP119 (MR4) blocked with 2.5% BSA/5% nor-
mal goat serum and MSP119-specific IgG was detected in pre-diluted serum samples using
HRP-conjugated goat anti-mouse-IgG, -IgG2b, or -IgM (Jackson ImmunoResearch). The Sure-
Blue ReserveTMB Kit (KPL) was used as substrate and absorbance was analyzed with a Spectra
Max 340 (Molecular Devices). For serum cytokine analyses, plates were coated with 2 μg/mL of
IL-10 or IFN-γ capture antibodies (eBioscience), blocked with 2.5% BSA/5% fetal calf serum.
Serum samples were subsequently applied at a 1:4 dilution. Wells were washed, incubated with
biotinylated detection antibodies (eBioscience) and developedwith streptavidin-HRP at room
temperature for 30 minutes before applying SureBlue ReserveTMB substrate as described
above.
In vitro T cell culture
Naïve CD4 T cells were enriched from spleens of Blimp-1-eYFP reporter mice and stimulated
with plate-bound α-CD3/α-CD28 for 3 days while treating with or without 1000 U/ml or 5000
U/ml of rIFNβ +/- blocking antibodies against IL-2 (JES6-1A12; used at a concentration of
10 μg /mL).
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Statistical analyses
Statistical analyses were performed using GraphPad Prism 6 software (GrapPad). Specific tests
of statistical significance are detailed in figure legends.
Supporting Information
S1 Fig. (A) Mice were infectedwith 106 P. yoelii infected red blood cells (pRBCs) and then
administered eitherMOPC (isotype) or α-IFNAR antibodies at the indicated time points
(arrows). Parasitemia (% of RBCs infected) kinetics from two independent experiments are
shown. (B-C) Representative dot plots illustrating that GC B cell (B) and Tfh (C) responses are
Plasmodium infection-induced.
(EPS)
S2 Fig. (A) Representative flow plots depicting the proportion of CD44hiBlimp-1-eYFP+
splenic CD4 T cells in naïve and Plasmodium infectedmice. (B) Representative flow plots
depicting the proportion of splenic GP61-80 specific CD4 T cells (left) and their subsequent
expression of Blimp-1-eYFP (right) 14 days following LCMV infection. (C) Summary data
(n = 5 mice/group) showing Blimp-1-eYFP expression (gMFI) in GP61-80 specific and effector
(CD44hiCD11ahi) CD4 T cells on day 14 post LCMV cl13 infection.
(EPS)
S3 Fig. (A-B). Analyses of LAG-3 and CD49b expression on Plasmodium infection-induced
CD44hiBlimp-1-eYFP+ splenic CD4 T cells on day 10 p.i. (C) Positive control staining to
verify CD49b reagent, which is also a pan-NK cell marker. NK cells were identified via
NK1.1 and CD3ε staining.
(EPS)
S4 Fig. (A) Representative flow plots showing the frequencyof splenic GC B cells in rIgG-,
α-IL-10R-, α-IFN-γ, or α-IFN-γ+α-IL-10R-treatedmice on d14 p.i. (B) Summary data
(n = 5 mice/group) depicting the frequency of GC B cells on day 14 p.i.
(EPS)
S5 Fig. (A) Representative dot plots and histograms depicting Tfh differentiation among
WT and ifnar-/- CD4 T cells recovered from the same Plasmodium-infected tcrα-/- mice on
day 14 p.i. (B) Summary graph displaying the total number of recovered WT and ifnar1-/-
CD44hi effector CD4+ T cells. (C-D) Summary data showing proportion of Tfh cells (C)
among recovered WT and ifnar1-/- CD44hi CD4+ T cells and their expression of Bcl-6 (gMFI)
(D). (E-F) Representative dot plots depicting the proportion of PD-1hiCXCR5+ Tfh cells (E)
and GC B cells (F) recovered on day 23 p.i. from Plasmodium infectedmixed bone marrow chi-
meric mice with either WT (TWT) or ifnar-/- (Tifnar-/-) T cell compartments. (G) Summary data
depicting the total number of GC B cells in Plasmodium infected TWT and Tifnar-/- mice.
(EPS)
S6 Fig. (A) Representative flow plots depicting the proportion of GP61-80 specificCD4 T
cells and their subsequent expression of CD25 (right) on day 14 post LCMV clone 13 infec-
tion. (B) Cumulative data (Mean +/- SD) showing the relative expression of CD25 (gMFI) on
GP61-80 specific and splenic effector (CD44hiCD11ahi) CD4+ T cells on day 14 post LCMV
clone 13 infection from control and α-IFNAR-treated mice.
(EPS)
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